TONIX Pharmaceuticals, Inc. Completes Enrollment In BESTFIT Trial Of TNX-102 SL For Fibromyalgia
NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, today announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goal of 200 subjects.
Help employers find you! Check out all the jobs and post your resume.